Covid-19 in Morocco: what we know about the effectiveness of Sinopharm’s inactivated vaccine, according to a study

By Hajar Kharroubi on 08/05/2022 at 09:01

Sinopharm’s inactivated vaccine against Covid-19 offers “a high level of protection against serious and critical hospital admissions”. That’s according to the results of a study conducted between February 1 and June 30, 2021 among 348,190 adults aged 18 to 99.

hasHAS

In order to determine the effectiveness of Sinopharm’s inactivated vaccine against the risk of developing a severe form of Covid-19 requiring hospitalization, a study was carried out between 01.01ah February and June 30, 2021 with 348,190 adults aged 18 to 99 years. Of these, 140,892 had received two doses of the vaccine, 1,149 had received a booster dose and 206,149 were unvaccinated.

According to the authors of this study, the effectiveness of Sinopharm’s inactivated vaccine was consistent with the results of phase III clinical trials. Two doses of this vaccine therefore provide high protection against serious or critical hospitalizations related to Covid-19 in 18-59 year olds and are moderately effective in those over 60 years of age.

According to these results, all subjects who received a booster dose, the subject of this study, were not hospitalized, versus 91 in those who were co-vaccinated and 1,345 in those who were not. The booster dose should be evaluated, the researchers say, as it is highly recommended and used in Morocco and boosts immunity and limits hospitalizations.

In detail, the results of this study show that the unadjusted efficacy of the two-dose vaccine against severe or critical hospitalizations related to Covid-19 was 90.2%. After accounting for age, gender, etc., the protection from serious or critical hospitalization with two doses was 88.5%.

This two-dose adjusted protective efficacy in 18 to 60 year olds ranged from 93.9% to 100% and was 53.3% in adults 60 years and older. There were no major or critical hospitalizations among booster dose recipients, but there were too few booster dose recipients at the time of the study, the researchers report.

According to the authors of this study, the estimates of the protective effect of this vaccine are consistent with those from phase III clinical trials abroad. For example, in Argentina, the efficacy of this two-dose vaccine was 84% ​​in people ≥ 60 years of age. In a large cohort of healthcare workers in Peru, 50% were against infection and 94% against Covid-19-related mortality.

In a study in Hungary of 895,000 vaccinated people, two-dose protection was 69% against infection and 88% against Covid-19-related mortality. In the United Arab Emirates, a study conducted in people aged 15 and over showed that this vaccine reduced the risk of hospitalization by 79.8%.

Leave a Comment